Emerging drugs for axial spondyloarthritis including ankylosing spondylitis

Expert Opinion on Emerging Drugs

Volumn 18, Issue 1, 2013, Pages 71-86

  Busquets Perez, Noemi ^a   Marzo Ortega, Helena ^b   Emery, Paul ^c  

^a HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

Ankylosing spondylitis; Treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; APREMILAST; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GELATINASE B; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; LYMPHOTOXIN; NEUTROPHIL COLLAGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SARILUMAB; SECUKINUMAB; STROMELYSIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; VASCULOTROPIN;

ANAPHYLACTIC SHOCK; ANKYLOSING SPONDYLITIS; AXIAL SPONDYLARTHRITIS; AXIAL SPONDYLOARTHRITIS; AXIAL SPONDYLOARTHROPATHY; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; ENTERITIS; GASTROINTESTINAL DISEASE; HUMAN; INCIDENCE; INFECTION RISK; INFUSION RELATED REACTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMARKETING SURVEILLANCE; PREVALENCE; PSORIASIS; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; SPONDYLARTHRITIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESISTANT DEPRESSION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UVEITIS; VIRUS REACTIVATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE AND BONES; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; INTERLEUKINS; JOINTS; MOLECULAR TARGETED THERAPY; PHOSPHODIESTERASE INHIBITORS; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874631391     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2013.752815     Document Type: Review

References (113)

1. Wendling D, Prati C, Claudepierre P, et al. Non-radiographic spondyloarthritis: A theoretical concept or a real entity? Joint Bone Spine 2012; [Epub ahead of print]
2. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27(4):361-8
3. Wendling D, Prati C. Biologic agents for treating ankylosing spondylitis: beyond TNFalpha antagonists. Joint Bone Spine 2011;78(6):542-4
4. Carette S, Graham D, Little H, et al. The natural disease course of ankylosing spondylitis. Arthritis Rheum 1983;26(2):186-90 (Pubitemid 13190334)
5. Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70(8):1369-74
6. Sampaio-Barros PD, Bortoluzzo AB, Conde RA, et al. Undifferentiated spondyloarthritis: a longterm follow-up study. J Rheumatol 2010;37:1195-9
7. Mau W, Zeidler H, Mau R, et al. Outcome of possible ankylosing spondylitis in a 10 years' follow-up. Clin Rheumtol 1987;6:60-6
8. Rudwaleit M, Braun J, Sieper J. [ASAS classification criteria for axial spondyloarthritis]. Z Rheumatol 2009;68(7):591-3
9. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of assessment of spondyloarthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68(6):777-83
10. Salvadorini G, Bandinelli F, Delle Sedie A, et al. Ankylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decades. Clin Exp Rheumatol 2012;30(4):561-5
11. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52(6):1756-65 (Pubitemid 40852884)
12. Kroon F, Landewe R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71(10):1623-9
13. Haroon N, Kim TH, Inman RD. NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms? Ann Rheum Dis 2012;71(10):1593-5
14. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal antiinflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71(10):1616-22
15. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38(4):499-505
16. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52(2):582-91 (Pubitemid 40216323)
17. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54(7):2136-46 (Pubitemid 44051069)
18. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58(11):3402-12
19. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44(9):2112-17 (Pubitemid 33644055)
20. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48(4):1126-36 (Pubitemid 36418256)
21. Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2012; Epub ahead of print
22. Braun J, Baraliakos X, Hermann KG, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis 2012;71(6):878-84
23. Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67(3):340-5 (Pubitemid 351281268)
24. Heldmann F, Brandt J, van der Horst-Bruinsma IE, et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011;29(4):672-80
25. Martin-Mola E, Sieper J, Leirisalo-Repo M, et al. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28(2):238-45
26. Sieper J, van der Heijde D, Dougados M, et al. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71(5):700-6
27. van der Heijde D, Landewe R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58(10):3063-70
28. van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58(5):1324-31 (Pubitemid 351705922)
29. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003 Aug;48(8):2122-7 (Pubitemid 36959191)
30. Rodriguez Lozano C. Safety of biological therapies: new data from BIOBADASER. Reumatol Clin 2011;6S3:S1-6
31. Carmona L, Abasolo L, Descalzo MA, et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum 2011;41(1):71-80
32. Fernandez-Espartero MC, Perez-Zafrilla B, Naranjo A, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 2011;40(4):330-7
33. Dreyer L, Mellemkjaer L, Andersen AR, et al. Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides-a follow-up study from the DANBIO Registry. Ann Rheum Dis 2012; Epub ahead of print
34. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50(1):124-31
35. Busquets N, Tomero E, Descalzo MA, et al. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology (Oxford) 2011;50(11):1999-2004
36. Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 2009;48(9):1029-35
37. Bakland G, Nossent HC, Gran JT. Incidence and prevalence of ankylosing spondylitis in Northern Norway. Arthritis Rheum 2005;53(6):850-5 (Pubitemid 41811125)
38. Alamanos Y, Papadopoulos NG, Voulgari PV, et al. Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002. Rheumatology (Oxford) 2004;43(5):615-18 (Pubitemid 38628193)
39. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41(1):58-67 (Pubitemid 28041923)
40. Bonafede MM, Gandra SR, Watson C, et al. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther 2012;29(3):234-48
41. Boonen A, de Vet H, van der Heijde D, van der Linden S. Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review. J Rheumatol 2001;28(5):1056-62 (Pubitemid 32422589)
42. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl 2006;78:4-11 (Pubitemid 44360187)
43. Mattey DL, Packham JC, Nixon NB, et al. Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res Ther 2012;14(3):R127
44. Arends S, van der Veer E, Groen H, et al. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol 2011;38(8):1644-50
45. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008;67(4):511-17 (Pubitemid 351498433)
46. Woo JH, Lee HJ, Sung IH, Kim TH. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007;34(8):1753-9
47. Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007;74(3):304-5 (Pubitemid 46720037)
48. Arends S, van der Veer E, Kallenberg CG, et al. Baseline predictors of response to TNF-alpha blocking therapy in ankylosing spondylitis. Curr Opin Rheumatol 2012;24(3):290-8
49. Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011;70(6):973-81
50. Keller C, Webb A, Davis J. Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis 2003;62(12):1128-32 (Pubitemid 37500615)
51. Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33(10):927-31 (Pubitemid 24324807)
52. Bal A, Unlu E, Bahar G, et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007;26(2):211-15 (Pubitemid 46020247)
53. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361(9):888-98
54. Wendling D. IL-23 and IL-17 in ankylosing spondylitis. Rheumatol Int 2010;30(11):1547
55. Chen WS, Chang YS, Lin KC, et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc 2012;75(7):303-8
56. Castro A, Jerez MJ, Gil C, Martinez A. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 2005;25(2):229-44 (Pubitemid 40299847)
57. Kroegel C, Foerster M. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast. Expert Opin Investig Drugs 2007;16(1):109-24 (Pubitemid 44964170)
58. Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 2000;47(2-3):127-62 (Pubitemid 30394536)
59. Mihara M, Nishimoto N, Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 2005;5(5):683-90 (Pubitemid 40780551)
60. Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68(10):1580-4
61. Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 2006;65(6):713-20 (Pubitemid 43799168)
62. Hayer S, Niederreiter B, Nagelreiter I, et al. Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis. Ann Rheum Dis 2010;69(7):1403-6
63. Lekpa FK, Poulain C, Wendling D, et al. Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study. Arthritis Res Ther 2012;14(2):R53
64. Brulhart L, Nissen MJ, Chevallier P, Gabay C. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 2010;77(6):625-6
65. Henes JC, Horger M, Guenaydin I, et al. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis 2010;69(12):2217-18
66. Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J Rheumatol 2011;38(7):1527
67. Wendling D, Racadot E, Toussirot E, Wijdenes J. Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. Br J Rheumatol 1996;35(12):1330 (Pubitemid 27032963)
68. Tanaka T, Kuwahara Y, Shima Y, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum 2009;61(12):1762-4
69. Shima Y, Tomita T, Ishii T, et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod Rheumatol 2011;21(4):436-9
70. Dudler J, Aubry-Rozier B. Tocilizumab in axial apondylarthropathies: about 18 cases. Abstract EULAR 2011
71. del Castillo pinol N, Gossec L, Roux C, Dougados M. Tocilizumab for treatment of refractory spondyloarthritis: report of 5 patients. Abstract EULAR 2011
72. Wendling D, Bossert M, Prati C. Short-term effect of IL-6 inhibition in spondylarthritis. Joint Bone Spine 2010;77(6):624-5
73. Sieper J, Thompson L, Harari O, Dougados M. TOCILIZUMAB (TCZ) is not effective for the treatment of Ankylosing Spondylitis (AS): results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial. Abstract EULAR 2012
74. Sieper J, Inman R, Badalamenti S, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized. Double-blind, placebo-controlled, international study (ALIGN). Abstract EULAR 2012
75. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41(12):2196-204 (Pubitemid 29009378)
76. McGarry F, Neilly J, Anderson N, et al. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology (Oxford) 2001;40(12):1359-64
77. Maksymowych WP, Jhangri GS, Fitzgerald AA, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46(3):766-73 (Pubitemid 34214258)
78. Jimi E, Nakamura I, Duong LT, et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 1999;247(1):84-93 (Pubitemid 29393964)
79. Tan AL, Marzo-Ortega H, O'Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004;63(9):1041-5 (Pubitemid 39120352)
80. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005;64(2):296-8 (Pubitemid 40193630)
81. Appel H, Maier R, Loddenkemper C, et al. Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. J Rheumatol 2010;37(4):823-8
82. Appel H, Loddenkemper C, Grozdanovic Z, et al. Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006;8(5):R143
83. Huang Y, Cheng F, Zhang X, Tang J. Marked reduction of sacroiliac joint inflammation on magnetic resonance imaging in a patient with ankylosing spondylitis after rituximab treatment. J Rheumatol 2011;38(9):2083-4
84. Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010;62(5):1290-7
85. Nocturne G, Dougados M, Constantin A, et al. Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry. Ann Rheum Dis 2010;69(2):471-2
86. Rodriguez-Escalera C, Fernandez-Nebro A. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology (Oxford) 2008;47(11):1732-3
87. Wendling D, Auge B, Streit G, et al. Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis. Joint Bone Spine 2008;75(4):510-11
88. Wendling D, Dougados M, Berenbaum F, et al. Rituximab Treatment for Spondyloarthritis. A Nationwide Series: data from the AIR Registry of the French Society of Rheumatology. J Rheumatol 2012; Epub ahead of print
89. Hardcastle SA, Gibbs S, Williamson L. Atypical psoriasis following rituximab for rheumatoid arthritis. J Rheumatol 2012;39(6):1303-4
90. Olivieri I, D'Angelo S, Leccese P, et al. Worsening of psoriasis with rituximab therapy. Clin Exp Rheumatol 2010;28(6):926
91. Thomas L, Canoui-Poitrine F, Gottenberg JE, et al. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry. J Rheumatol 2012;39(5):893-8
92. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353(11):1114-23 (Pubitemid 41317434)
93. Bollow M, Fischer T, Reisshauer H, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000;59(2):135-40 (Pubitemid 30305612)
94. Zou J, Zhang Y, Thiel A, et al. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology (Oxford) 2003;42(7):846-55 (Pubitemid 37220933)
95. Zou J, Appel H, Rudwaleit M, et al. Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Ann Rheum Dis 2005;64(5):722-9 (Pubitemid 40559299)
96. Baeten D, Sieper J, Emery P, et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Abstract ACR 2011. Abstract number 779
97. Baraliakos X, Braun J, Laurent D, et al. Interleukin-17A blockade with secukinumab reduces spinal inflammation in patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging. Abstract ACR 2011. Abstract number 2486D
98. Zhang R, Qian J, Guo J, et al. Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody. Curr Eye Res 2009;34(4):297-303
99. Leonardi C. Response to brodalumab and ixekizumab, anti-interleukin-17- receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol 2012;167(4):714-15
100. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13):1190-9
101. Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis 2012; Epub ahead of print
102. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58(7):1981-91 (Pubitemid 351988090)
103. Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009;60(4):946-54
104. Moghimi J, Sheikhvatan M, Semnani V. The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series. Rheumatol Int 2012;32(8):2271-4
105. Jois RN, Leeder J, Gibb A, et al. Low-dose infliximab treatment for ankylosing spondylitis-clinically- and cost-effective. Rheumatology (Oxford) 2006;45(12):1566-9 (Pubitemid 44817066)
106. Wendling D, Prati C, Goupille P, Mulleman D. Optimizing TNFalpha antagonist therapy in patients with spondyloarthritis: why and how? Joint Bone Spine 2011;78(3):225-7
107. Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7(3):R439-44
108. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005;44(3):342-8 (Pubitemid 40361291)
109. Goldminz AM, Gottlieb AB. Ustekinumab for psoriasis and psoriatic arthritis. J Rheumatol Suppl 2012;89:86-9
110. Leah E. Clinical trials: phase III trial results for tofacitinib bring new oral DMARD therapy a step closer for patients with rheumatoid arthritis. Nat Rev Rheumatol 2012;8(10):561
111. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011;63(2):337-45
112. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011;70(6):1108-10
113. Lekpa FK, Farrenq V, Canou?- Poitrine F, et al. Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 2012;79(1):47-50